NEFL and Alzheimer disease: The present study highlights several more established markers that tag the following processes: (1) neuroinflammation and glial activation (interleukin‐6 [IL‐6], S100 calcium‐binding protein B [S100B], triggering receptor expressed on myeloid cells [sTREM2], chitinase‐3‐like protein 1 [YKL‐40], and glial fibrillary acidic protein [GFAP]), (2) synaptic dysfunction (neurogranin [Ng]), and (3) neurodegeneration (total α‐synuclein [α‐Syn] and neurofilament light chain protein [NfL]), all of which change unfavorably with age or AD.